Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cabaletta Bio ( (CABA) ) has issued an update.
On October 27, 2025, Cabaletta Bio announced positive clinical data and development updates from its RESET-Myositis, RESET-SSc, and RESET-SLE trials at the ACR Convergence 2025. The trials evaluate rese-cel, a CAR T cell therapy, showing promising results in autoimmune diseases like myositis, systemic sclerosis, and lupus. The company is initiating a myositis registrational trial and expanding its RESET-SLE trial to include a no preconditioning cohort, with initial data expected in 2026. These developments could significantly impact treatment options for autoimmune diseases, offering potential drug-free clinical responses.
The most recent analyst rating on (CABA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page.
Spark’s Take on CABA Stock
According to Spark, TipRanks’ AI Analyst, CABA is a Underperform.
Cabaletta Bio’s overall score is low primarily due to its financial performance, marked by no revenue and increasing losses. The technical analysis indicates a bearish trend, further impacting the score. However, the recent positive clinical trial data provides a glimmer of hope, slightly improving future outlook. Despite this, the stock’s valuation remains a concern, making it a risky investment at this stage.
To see Spark’s full report on CABA stock, click here.
More about Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on developing curative targeted cell therapies specifically for patients with autoimmune diseases. The company is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, evaluated under the RESET clinical development program across various therapeutic areas including rheumatology, neurology, and dermatology.
Average Trading Volume: 2,746,508
Technical Sentiment Signal: Hold
Current Market Cap: $225.9M
See more data about CABA stock on TipRanks’ Stock Analysis page.